Filing Flows › Pacira BioSciences (PCRX) › Operating margin
Pacira BioSciences (PCRX) operating margin by quarter
Pacira BioSciences' operating margin was 12.6% in Q3 2026 (third quarter 2026), +10.4 pts from Q2 2026. Over the last 6 quarters it ranged from 1.2% (Q1 2025) to 12.6% (Q3 2026).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 12.6% | +10.4 pts | +9.1 pts |
| Q2 2026 | 2.2% | -1.7 pts | — |
| Q1 2026 | 3.9% | +2.7 pts | +2.7 pts |
| Q4 2025 | 1.2% | -2.4 pts | — |
| Q3 2025 | 3.5% | +2.4 pts | — |
| Q1 2025 | 1.2% | — | — |
Q3 2026 at a glance
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Pacira BioSciences' operating margin?
Pacira BioSciences' operating margin was 12.6% in Q3 2026 (third quarter 2026), +10.4 pts from Q2 2026.
How has Pacira BioSciences' operating margin changed?
Over the last 6 quarters it ranged from 1.2% (Q1 2025) to 12.6% (Q3 2026).